The DOI matches its Crossref record.
Systemic therapy of myeloma xenografts by an attenuated measles virus
Open accessAbstract
Conditionally replicating viruses are promising agents for the treatment of malignancy. Here it is shown that the live attenuated Edmonston-B vaccine strain of measles virus (MV-Edm) replicates selectively in human myeloma cells and has potent antitumor activity. In vitro, replication of MV-Edm was restricted in phytohemagglutinin (PHA)-stimulated peripheral blood lymphocytes (PBLs) but proceeded efficiently in a panel of 6 myeloma cell lines—ARH-77, RPMI 8226, JJN-3, MM1, KAS-6/1, and KMS-11—and in primary myeloma cells isolated by CD138 sorting from the bone marrow aspirates of 6 patients. MV-Edm infection induced potent cytopathic effects in these myeloma cells, resulting in the formation of multinucleated syncytia that eventually became nonviable. In contrast, syncytial formation in PHA-stimulated PBLs was minimal after MV-Edm infection. In vivo, MV-Edm was antitumorigenic and inhibited the establishment of myeloma cells as xenografts in immunocompromised mice. When injected directly into ARH-77 myeloma xenografts in the mice, MV-Edm caused complete regression of these xenografts. MV-Edm administered intravenously into the tail veins of mice also showed significant antineoplastic activity against established RPMI 8226 and ARH-77 xenografts. In particular, the ARH-77 myeloma xenografts were exquisitely sensitive to MV-Edm therapy, and tumors in all mice regressed completely. In light of its selectivity for myeloma cells and its potent antineoplastic activity against myeloma xenografts in vivo, MV-Edm merits further development for the treatment of multiple myeloma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Cattaneo, R., Miest, T., Shashkova, E. V., & Barry, M. A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1927 · Cited by 373
Self-citationDingli, D., Peng, K.-W., Harvey, M. E., Greipp, P. R., O'Connor, M. K., Cattaneo, R., Morris, J. C., & Russell, S. J. (2004) · Blood · doi:10.1182/blood-2003-07-2233 · Cited by 320
Self-citationThe Na+/I− Symporter (NIS): Mechanism and Medical Impact
Portulano, C., Paroder-Belenitsky, M., & Carrasco, N. (2014) · Endocrine Reviews · doi:10.1210/er.2012-1036 · Cited by 319
High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles Virus
Anderson, B. D., Nakamura, T., Russell, S. J., & Peng, K.-W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0884 · Cited by 315
Self-citationKim, J. H., Oh, J. Y., Park, B. H., Lee, D. E., Kim, J. S., Park, H. E., Roh, M. S., Je, J. E., Yoon, J. H., Thorne, S. H., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.008 · Cited by 303
The Sodium/Iodide symporter (NIS): Molecular physiology and preclinical and clinical applications
Ravera, S., Reyna-Neyra, A., Ferrandino, G., Amzel, L. M., & Carrasco, N. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034125 · Cited by 298
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Tian, Y., Xie, D., & Yang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 293
Oncolytic Immunovirotherapy for Melanoma Using Vesicular Stomatitis Virus
Diaz, R. M., Galivo, F., Kottke, T., Wongthida, P., Qiao, J., Thompson, J., Valdes, M., Barber, G., & Vile, R. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3974 · Cited by 264
Rescue and propagation of fully retargeted oncolytic measles viruses
Nakamura, T., Peng, K.-W., Harvey, M., Greiner, S., Lorimer, I. A. J., James, C. D., & Russell, S. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1060 · Cited by 252
Self-citation
Metadata
- Authors
- Peng, K.-W., Ahmann, G. J., Pham, L., Greipp, P. R., Cattaneo, R., & Russell, S. J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2001-10-01
- Volume
- 98
- Issue
- 7
- Pages
- 2002-2007
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2038237282
- Cited by
- 181
- References
- 0
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.